Teva And Celltrion Gain Arthritis Advantage On Rituximab

Truxima Biosimilar Now Available In Rheumatoid Arthritis Indication In US

06 May 2020

• By Akriti Seth and Dave Wallace

Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.

Watch_Face_Advantage — Teva is aiming to take advantage of its exclusive indication for its rituximab biosimilar • Source: Shutterstock

Teva and Celltrion’s Truxima (rituximab-abbs) biosimilar is now indicated to treat rheumatoid arthritis in the US, the firms have revealed, making it “the only biosimilar to the reference product Rituxan available to treat rheumatoid arthritis in the US.”

At the same time, the companies have also added granulomatosis with polyangiitis and microscopic